Merkel Cell Carcinoma, Version 1.2024 Featured Updates to the NCCN Guidelines

Chrysalyne D. Schmults; Rachel Blitzblau; Sumaira Z. Aasi; Murad Alam; Arya Amini; Kristin Bibee; Diana Bolotin; Jeremy Bordeaux; Pei Ling Chen; Carlo M. Contreras; Dominick DiMaio; Jessica M. Donigan; Jeffrey M. Farma; Karthik Ghosh; Kelly Harms; Alan L. Ho; John Nicholas Lukens; Susan Manber; Lawrence Mark; Theresa Medina; Kishwer S. Nehal; Paul Nghiem; Kelly Olino; Soo Park; Tejesh Patel; Igor Puzanov; Jason Rich; Aleksandar Sekulic; Ashok R. Shaha; Divya Srivastava; Valencia Thomas; Courtney Tomblinson; Puja Venkat; Yaohui Gloria Xu; Siegrid Yu; Mehran Yusuf; Beth McCullough; Sara Espinosa

doi:10.6004/jnccn.2024.0002

Merkel Cell Carcinoma, Version 1.2024 Featured Updates to the NCCN Guidelines

Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Diana Bolotin, Jeremy Bordeaux, Pei Ling Chen, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Kelly Harms, Alan L. Ho, John Nicholas Lukens, Susan Manber, Lawrence Mark, Theresa MedinaKishwer S. Nehal, Paul Nghiem, Kelly Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, Aleksandar Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja Venkat, Yaohui Gloria Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, Sara Espinosa

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments fromexpert review frompanelmembers, institutional review, as well as submissions from within NCCN and external organizations. TheseNCCNGuidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC."This new algorithmpage addresses locally advanced disease, and the panel clarifies the meaning behind the term "nonsurgical"by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.

Original language	English
Article number	e240002
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	22
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2024.0002
State	Published - Jan 2024

Access to Document

10.6004/jnccn.2024.0002

Cite this

Schmults, C. D., Blitzblau, R., Aasi, S. Z., Alam, M., Amini, A., Bibee, K., Bolotin, D., Bordeaux, J., Chen, P. L., Contreras, C. M., DiMaio, D., Donigan, J. M., Farma, J. M., Ghosh, K., Harms, K., Ho, A. L., Lukens, J. N., Manber, S., Mark, L., ... Espinosa, S. (2024). Merkel Cell Carcinoma, Version 1.2024 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 22(1), Article e240002. https://doi.org/10.6004/jnccn.2024.0002

@article{7522888117aa469a878a38a183c07e35,

title = "Merkel Cell Carcinoma, Version 1.2024 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments fromexpert review frompanelmembers, institutional review, as well as submissions from within NCCN and external organizations. TheseNCCNGuidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled {"}Clinical N0 Disease, Locally Advanced MCC.{"}This new algorithmpage addresses locally advanced disease, and the panel clarifies the meaning behind the term {"}nonsurgical{"}by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.",

author = "Schmults, {Chrysalyne D.} and Rachel Blitzblau and Aasi, {Sumaira Z.} and Murad Alam and Arya Amini and Kristin Bibee and Diana Bolotin and Jeremy Bordeaux and Chen, {Pei Ling} and Contreras, {Carlo M.} and Dominick DiMaio and Donigan, {Jessica M.} and Farma, {Jeffrey M.} and Karthik Ghosh and Kelly Harms and Ho, {Alan L.} and Lukens, {John Nicholas} and Susan Manber and Lawrence Mark and Theresa Medina and Nehal, {Kishwer S.} and Paul Nghiem and Kelly Olino and Soo Park and Tejesh Patel and Igor Puzanov and Jason Rich and Aleksandar Sekulic and Shaha, {Ashok R.} and Divya Srivastava and Valencia Thomas and Courtney Tomblinson and Puja Venkat and Xu, {Yaohui Gloria} and Siegrid Yu and Mehran Yusuf and Beth McCullough and Sara Espinosa",

year = "2024",

month = jan,

doi = "10.6004/jnccn.2024.0002",

language = "English",

volume = "22",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "1",

}

Schmults, CD, Blitzblau, R, Aasi, SZ, Alam, M, Amini, A, Bibee, K, Bolotin, D, Bordeaux, J, Chen, PL, Contreras, CM, DiMaio, D, Donigan, JM, Farma, JM, Ghosh, K, Harms, K, Ho, AL, Lukens, JN, Manber, S, Mark, L, Medina, T, Nehal, KS, Nghiem, P, Olino, K, Park, S, Patel, T, Puzanov, I, Rich, J, Sekulic, A, Shaha, AR, Srivastava, D, Thomas, V, Tomblinson, C, Venkat, P, Xu, YG, Yu, S, Yusuf, M, McCullough, B & Espinosa, S 2024, 'Merkel Cell Carcinoma, Version 1.2024 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 22, no. 1, e240002. https://doi.org/10.6004/jnccn.2024.0002

TY - JOUR

T1 - Merkel Cell Carcinoma, Version 1.2024 Featured Updates to the NCCN Guidelines

AU - Schmults, Chrysalyne D.

AU - Blitzblau, Rachel

AU - Aasi, Sumaira Z.

AU - Alam, Murad

AU - Amini, Arya

AU - Bibee, Kristin

AU - Bolotin, Diana

AU - Bordeaux, Jeremy

AU - Chen, Pei Ling

AU - Contreras, Carlo M.

AU - DiMaio, Dominick

AU - Donigan, Jessica M.

AU - Farma, Jeffrey M.

AU - Ghosh, Karthik

AU - Harms, Kelly

AU - Ho, Alan L.

AU - Lukens, John Nicholas

AU - Manber, Susan

AU - Mark, Lawrence

AU - Medina, Theresa

AU - Nehal, Kishwer S.

AU - Nghiem, Paul

AU - Olino, Kelly

AU - Park, Soo

AU - Patel, Tejesh

AU - Puzanov, Igor

AU - Rich, Jason

AU - Sekulic, Aleksandar

AU - Shaha, Ashok R.

AU - Srivastava, Divya

AU - Thomas, Valencia

AU - Tomblinson, Courtney

AU - Venkat, Puja

AU - Xu, Yaohui Gloria

AU - Yu, Siegrid

AU - Yusuf, Mehran

AU - McCullough, Beth

AU - Espinosa, Sara

PY - 2024/1

Y1 - 2024/1

N2 - The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments fromexpert review frompanelmembers, institutional review, as well as submissions from within NCCN and external organizations. TheseNCCNGuidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC."This new algorithmpage addresses locally advanced disease, and the panel clarifies the meaning behind the term "nonsurgical"by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.

AB - The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments fromexpert review frompanelmembers, institutional review, as well as submissions from within NCCN and external organizations. TheseNCCNGuidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC."This new algorithmpage addresses locally advanced disease, and the panel clarifies the meaning behind the term "nonsurgical"by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.

UR - http://www.scopus.com/inward/record.url?scp=85182826064&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2024.0002

DO - 10.6004/jnccn.2024.0002

M3 - Article

C2 - 38244274

AN - SCOPUS:85182826064

SN - 1540-1405

VL - 22

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

M1 - e240002

ER -

Merkel Cell Carcinoma, Version 1.2024 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this